[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"preference-patient\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:preference-patient":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100649105","one-page-truth-telling-aid-for-cancer-disclosure-100649105",false,"NCT07730164","One-Page Truth-Telling Aid for Cancer Disclosure","A One-Page Truth-Telling Aid for Cancer Disclosure in Taiwan: A Two-Arm Pragmatic Randomized Controlled Trial","【Physicians】\n\n* Inclusion Criteria:\n\n  * Physicians who provide clinical care for patients with cancer in participating outpatient departments.\n  * Physicians who are involved in cancer-related truth-telling or disclosure consultations.\n  * Physicians who are willing to participate and provide informed consent.\n* Exclusion Criteria:\n\n  * Physicians who are unable or unwilling to complete study procedures or follow-up assessments.\n\n【Patients】\n\n* Inclusion Criteria:\n\n  * Patients diagnosed with cancer.\n  * Patients who are scheduled to receive cancer-related information from a participating physician, including information about diagnosis, recurrence, metastasis, end-of-life status.\n  * Patients who are able to communicate in Mandarin Chinese or Taiwanese.\n  * Patients who are able to complete questionnaires independently or with assistance from the research assistant.\n  * Patients who are willing to participate and provide informed consent.\n* Exclusion Criteria:\n\n  * Patients who are unable to provide informed consent.\n  * Patients with severe cognitive impairment, severe physical illness, or emotional distress that prevents participation, as judged by the clinical team or research staff.\n  * Patients who are unable to complete the study questionnaires even with assistance.","ALL",{"count":18,"type":19},400,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this clinical trial is to learn whether a one-page communication aid can improve communication between physicians and patients with cancer during cancer-related truth-telling consultations. The one-page aid is designed to help physicians quickly understand patients' preferences and needs before the consultation.\n\nThe main questions it aims to answer are:\n\n* Does the one-page communication aid improve patients' satisfaction with how cancer-related information is explained?\n* Does the one-page communication aid reduce patients' emotional distress after the consultation?\n* Does the one-page communication aid improve physicians' confidence in communicating cancer-related information?\n\nResearchers will compare patients whose physicians receive the one-page communication aid with patients whose physicians provide usual care with a blank sheet for patients to write down questions. This comparison will help determine whether the one-page aid improves communication, emotional outcomes, and physician confidence.\n\nParticipants will:\n\n* Complete questionnaires before and after the consultation\n* Receive either the one-page communication aid or a blank sheet, depending on their physician's group\n* Complete follow-up questionnaires at 3 months and 6 months after the consultation\n\nPhysicians will also complete brief questionnaires about their communication confidence at baseline, 1 week after recruitment of their first enrolled patient, 3 months, and 6 months.",[25,26,27,28,29,30],"Neoplams","Physician-Patient Relations","Communication Research","Disclosure","Communication About Health Information","Preference, Patient",[32],"Cancer truth-telling; disclosure preferences; physician-patient communication; communication aid; oncology care; psychooncology","RECRUITING","2026-07-22",{"date":36,"type":37},"2026-07-28","ACTUAL",{"date":39,"type":37},"2025-11-27",{"date":41,"type":19},"2027-07",{"name":43,"class":44},"Chang Gung University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100584796","patient-preferences-on-same-day-bilateral-intravitreal-dexamethasone-injections-100584796","NCT06894017","Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections","Inclusion criteria\n\n* Having received at least one intravitreal dexamethasone implant in either eye\n* \\>18 years of age\n* Capacity to comprehend and answer questions in Danish language\n* Signed informed consent\n\nExclusion criteria\n\n• No intravitreal dexamethasone implant received within the last 12 months","18 Years",{"count":54,"type":19},200,"OBSERVATIONAL","Intravitreal injections with dexamethasone implant (Ozurdex®) provide a reasonable and long-lasting treatment option in the cases of diabetic macular edema, as well as macular edema resulting from retinal vein occlusion and noninfectious posterior uveitis. During the course of these diseases, both eyes may be affected and may need therapy. The treatment burden associated with frequent medical visits associated with treatments in both eyes and follow-ups can be significant for patients and caregivers alike. Same-session bilateral ophthalmic procedures have proven safe and cost-effective, with patients consistently expressing a strong preference for this approach, particularly in the cases of cataract surgery and anti-VEGF injections when given the choice. The safety profile of same-day bilateral dexamethasone injections aligns with those of unilateral injections.\n\nThis patient preference study will focus on addressing the practical aspects of same-day bilateral dexamethasone injections from the patients' perspective and aims to explore the impact of personal and socio-economic variables, and the overall perspective of patients on choosing same-day bilateral dexamethasone injections. Understanding and mitigating the challenges patients face can lead to a more patient-friendly and resource-saving approach. Based on the outcomes of this study, considerations may be made to introduce bilateral injections at our department, potentially optimizing patient experience and clinical resources.\n\nThe aim of the study is to establish patient preferences regarding the administration of intravitreal dexamethasone implant injections in both eyes on the same day, in the same session and to identify key motivating and limiting factors from the patients' perspective.",[58,30],"Informed Consent",[60,61,62,63,64,65,66],"Intravitreal","dexamethasone","injections","implant","questionnaire","patient preference","bilateral","2025-07-22",{"date":69,"type":37},"2025-07-24",{"date":71,"type":37},"2025-01-13",{"date":73,"type":19},"2026-01",{"name":75,"class":44},"Rigshospitalet, Denmark"]